DiaMedica Historical Income Statement
| DMAC Stock | USD 5.66 0.45 8.64% |
Historical analysis of DiaMedica Therapeutics income statement accounts such as Total Revenue of 0.0 or Other Operating Expenses of 22.3 M can show how well DiaMedica Therapeutics performed in making a profits. Evaluating DiaMedica Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of DiaMedica Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining DiaMedica Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether DiaMedica Therapeutics is a good buy for the upcoming year.
DiaMedica |
About DiaMedica Income Statement Analysis
DiaMedica Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to DiaMedica Therapeutics shareholders. The income statement also shows DiaMedica investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
DiaMedica Therapeutics Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of DiaMedica Therapeutics. It is also known as DiaMedica Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from DiaMedica Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into DiaMedica Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DiaMedica Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.At present, DiaMedica Therapeutics' Other Operating Expenses is projected to increase significantly based on the last few years of reporting. The current year's Research Development is expected to grow to about 13.8 M, whereas Depreciation And Amortization is forecasted to decline to about 28.5 K.
| 2023 | 2024 (projected) | Reconciled Depreciation | 28K | 21.7K | Interest Income | 44.9K | 47.1K |
DiaMedica Therapeutics income statement Correlations
Click cells to compare fundamentals
DiaMedica Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
DiaMedica Therapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 877K | 21K | 24K | 25K | 30K | 28.5K | |
| Interest Expense | 119K | 229K | 82K | 353K | 406.0K | 426.2K | |
| Other Operating Expenses | 10.7M | 12.5M | 13.6M | 14.0M | 21.3M | 22.3M | |
| Operating Income | (11.6M) | (12.7M) | (13.6M) | (14.0M) | (21.3M) | (20.2M) | |
| Ebit | (11.6M) | (12.3M) | (13.6M) | (14.0M) | (19.3M) | (18.4M) | |
| Research Development | 7.9M | 8.3M | 8.8M | 7.8M | 13.1M | 13.8M | |
| Ebitda | (10.7M) | (12.2M) | (13.6M) | (14.0M) | (19.3M) | (18.3M) | |
| Total Operating Expenses | 10.7M | 12.5M | 13.6M | 14.0M | 21.3M | 22.3M | |
| Income Before Tax | (10.6M) | (12.3M) | (13.6M) | (13.6M) | (19.3M) | (18.4M) | |
| Total Other Income Expense Net | 975K | 434K | 82K | 353K | 1.9M | 2.0M | |
| Net Income | (10.6M) | (12.3M) | (13.6M) | (13.7M) | (19.4M) | (18.4M) | |
| Income Tax Expense | 80K | 31K | 27K | 28K | 43K | 45.2K | |
| Selling General Administrative | 3.7M | 4.4M | 4.9M | 6.2M | 8.2M | 8.6M | |
| Net Income From Continuing Ops | (10.6M) | (12.3M) | (13.6M) | (13.7M) | (18.0M) | (17.1M) | |
| Net Income Applicable To Common Shares | (5.7M) | (10.6M) | (12.3M) | (13.6M) | (12.2M) | (11.6M) | |
| Tax Provision | 80K | 31K | 27K | 28K | 32.2K | 33.6K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether DiaMedica Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of DiaMedica Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Diamedica Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Diamedica Therapeutics Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DiaMedica Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DiaMedica Therapeutics. If investors know DiaMedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DiaMedica Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.56) | Return On Assets (0.24) | Return On Equity (0.35) |
The market value of DiaMedica Therapeutics is measured differently than its book value, which is the value of DiaMedica that is recorded on the company's balance sheet. Investors also form their own opinion of DiaMedica Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is DiaMedica Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DiaMedica Therapeutics' market value can be influenced by many factors that don't directly affect DiaMedica Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DiaMedica Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if DiaMedica Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DiaMedica Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.